本文已被：浏览 695次 下载 336次
投稿时间：2020-02-10 网络发布日期：2020-08-20
投稿时间：2020-02-10 网络发布日期：2020-08-20
中文摘要: 目的 探讨长链非编码叉头框蛋白C2-反义RNA1(LncRNA FOXC2-AS1)在弥漫大B细胞淋巴瘤(DLBCL)组织中的表达及意义。方法 选取2012年4月至2017年4月收治的DLBCL患者93例和同期因淋巴结反应性增生就诊的45例患者（对照组）作为研究对象。实时荧光定量PCR术检测DLBCL患者淋巴瘤组织和对照组淋巴结组织标本中LncRNA FOXC2-AS1表达；分析LncRNA FOXC2-AS1在不同病理特征DLBCL患者中的表达差异,以及对患者预后的影响。结果 LncRNA FOXC2-AS1在DLBCL患者组织中的相对表达量为2.47±0.34,高于对照组组织中的1.03±0.12,差异有统计学意义(P<0.01);LncRNA FOXC2-AS1在有B症状（发热、乏力、盗汗和消瘦）、B细胞淋巴瘤-2（Bcl-2）阳性、多发骨髓瘤癌基因1（MUM1）阳性、、Ki-67阳性、LDH升高、结外病变数量>2个、Arbor临床分期Ⅲ~Ⅳ期、IPI评分>2分和治疗效果未完全缓解的DLBCL患者组织中表达量升高(P<0.05,P<0.01);Kaplan-Meier生存分析结果显示,低表达组患者平均生存时间［(62.83±6.00)月vs(33.48±3.28)月］和累积生存率（66.67% vs 21.74%）均高于高表达组（P<0.01）;Cox比例风险回归模型结果显示,Bcl-2、LDH、Arbor临床分期、治疗效果和LncRNA FOXC2-AS1表达是影响DLBCL患者预后的风险因素(HR=1.943、2.077、2.115、2.082、2.966,P<0.05)。结论 LncRNA FOXC2-AS1在DLBCL组织中呈高表达,且可能与其恶性增殖、侵袭及治疗效果有关,是影响患者预后的指标。
中文关键词: 弥漫大B细胞淋巴瘤 长链非编码叉头框蛋白C2-反义RNA1 预后
Abstract:ObjectiveTo investigate the expression and significance of long-chain non-coding RNA FOXC2-AS1 (LncRNA FOXC2-AS1) in diffuse large B-cell lymphoma (DLBCL) tissues.MethodsNinety-three patients with DLBCL admitted from April 2012 to April 2017 were selected as DLBCL group and during the same period,45 patients with lymph node reactive hyperplasia were collected as control group.Real-time fluorescence quantitative PCR was used to detect the expression of LncRNA FOXC2-AS1 in lymphoma tissues of DLBCL patients and lymph node tisssues of control group.The expression difference of LncRNA FOXC2-AS1 in DLBCL patients with different pathological indicators and their effects on the prognosis of patients were analyzed.ResultsThe expression level of LncRNA FOXC2-AS1 in DLBCL goup was significantly higher than that in control group (2.47±0.34 vs 1.03±0.12,P<0.01).The expression of LncRNA FOXC2-AS1 increased in patients with B symptoms,Bcl-2 positive,MUM1 positive,Ki-67 positive,higher LDH,the number of extranodal lesions>2,Arbor clinical stage Ⅲ~Ⅳ,IPI score> 2 points and the treatment effect not completely relieved(P<0.05).Kaplan-Meier survival analysis showed that the average survival time ［(62.83±6.00) months vs (33.48±3.28) months,P<0.01］ and cumulative survival rate(66.67% vs 21.74%,P<0.01)of patients in the low expression group were higher than those in the high expression group.Cox proportional hazards regression model results showed that Bcl-2,LDH,Arbor clinical stage,treatment effect and LncRNA FOXC2-AS1 expression were risk factors that affect the prognosis of DLBCL patients (HR=1.943,2.077,2.115,2.082,2.966,P<0.05).ConclusionLncRNA FOXC2-AS1 is highly expressed in DLBCL tissues,and may be related to its malignant proliferation,invasion and treatment effect,which is an indicator that affects the prognosis of patients.
文章编号： 中图分类号： 文献标志码：A
基金项目:河南省科技发展计划(152300410161)
| 作者 | 单位 |
| 刘伟1 | 1.榆林市第一医院血液科,陕西 榆林719000； |
| 雷磊1 | 1.榆林市第一医院血液科,陕西 榆林719000； |
| 叶绥艳1 | 1.榆林市第一医院血液科,陕西 榆林719000； |
| 刘强2 | 2.河南省肿瘤医院血液科,河南 郑州450052 |
| Author Name | Affiliation |
| LIU Wei*,LEI Lei,YE Sui-yan,LIU Qiang | *Department of Hematology,the First Hospital of Yulin,Yulin,Shaanxi 719000,China |
引用文本：
刘伟,雷磊,叶绥艳,等.长链非编码RNA FOXC2-AS1在弥漫大B细胞淋巴瘤组织中的表达及意义[J].中国临床研究,2020,33(8):1023-1026.
刘伟,雷磊,叶绥艳,等.长链非编码RNA FOXC2-AS1在弥漫大B细胞淋巴瘤组织中的表达及意义[J].中国临床研究,2020,33(8):1023-1026.